Prevention of tuberculosis (BCG vaccine)
Conditions
Interventions
The study will be structured as a two-arm cluster RCT. One arm (83 clinics) will serve as the control and will operate as the status quo, while the other arm (84 clinics) will receive New Incentives f
Sponsors
GiveWell
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Children aged 0 to 16 months can be enrolled in the program and incentives paid to their caregivers 2. Children aged 12 to 16 months will have their data measured at endline 3. All participants must reside in study clinic catchment areas. 4. Vaccination status will be measured by caregiver survey. Caregivers must consent to the survey
Exclusion criteria
Exclusion criteria: 1. Residence outside the study area (self-reported) 2. Outside the age range (self-reported)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 12/12/2019: 1. The probability that a 12- to 16-month-old in a community served by a program clinic received BCG 2. The probability that a 12- to 16-month-old in a community served by a program clinic received at least one dose of PENTA 3. The probability that a 12- to 16-month-old in a community served by a program clinic received Measles 1 Previous primary outcome measures: 1. The odds that a 12- to 16-month-old in a community served by a program clinic received BCG 2. The odds that a 12- to 16-month-old in a community served by a program clinic received at least one dose of PENTA 3. The odds that a 12- to 16-month-old in a community served by a program clinic received Measles 1 Data collection takes place at three points (baseline, midline, and endline) using a series of self-reported surveys of caregivers, examination of the child's health card (where available) and reviewing clinic records. Baseline was completed between August and October 2017, midline is scheduled for March 2019, and endline is planned for November 2019 to January 2020. Across all outcome measurements, sampled infants will be aged between 12 and 16 months (though baseline surveyed some infants aged up to 24 months to increase sample size). We sample these age groups as they are well beyond the age at which children should receive the program vaccinations. (The Nigerian Routine Immunization schedule aims to give the vaccinations we measure between birth and 9 months old.) We do not follow the same infants from baseline to midline to endline but, rather, compare coverage rates in the same age group at each point in time. | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 12/12/2019: 1. The probability that a 12- to 16-month-old in a community served by a program clinic is fully immunized (loose and strict) 2. The timeliness of vaccination, particularly for Measles 1, among 12- to 16-month-olds in communities served by a program clinic 3. The average number of vaccines received per 12- to 16-month-old child in communities served by a program clinic 4. The percentage of 12- to 16-month-olds in communities served by a program clinic who received at least one injectable vaccine 5. The probability that a 12- to 16-month-old in a community served by a study clinic received at least one dose of PCV 6. The change over time in the volume of BCG, Penta 1, Penta 2, Penta 3, and Measles vaccinations recorded in clinic administrative records between treatment and control Previous secondary outcome measures: 1. The odds that a 12- to 16-month-old in a community served by a program clinic is fully immunized (loose and strict) 2. The timeliness of vaccination, particularly for Measles 1, among 12- to 16-month-olds in communities served by a program clinic 3. The average number of vaccines received per 12- to 16-month-old child in communities served by a program clinic 4. The percentage of 12- to 16-month-olds in communities served by a program clinic who received at least one injectable vaccine Data collection takes place at three points (baseline, midline, and endline) using a series of self-reported surveys of caregivers, examination of the child's health card (where available) and reviewing clinic records. Baseline was completed between August and October 2017, midline is scheduled for March 2019, and endline is planned for November 2019 to January 2020. Across all outcome measurements, sampled in | — |
Countries
Nigeria
Contacts
Public ContactZack;Alison Devlin-Foltz;Connor
;
Outcome results
None listed